|
Market Cap (25-Jun) $8,266,923 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (1-Oct) 3,544 (0.00%) (548th) |
|
52w High $0.180 |
52w Low $0.075 |
P/E - |
EPS -0.01 |
IXC released this announcement to the ASX on 23 November 2021, 16:15. The announcement is not marked as price sensitive, and is 2 page(s) in length and 185.62kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.456% short sold according to ASIC data. It was ranked the 299th most shorted stock on the ASX. It remains ranked 548th as of the latest reported data (01 October 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Withdrawal of AGM Resolutions | 23 November 2021, 16:15 |
| Invex to Present at Bell Potter Healthcare Conference | 10 November 2021, 16:21 |
| Notice of Webinar & Investor Presentation | 4 November 2021, 14:41 |
| Global Phase 3 Trial of Presendin to Launch in Q4 2021 | 4 November 2021, 9:12 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 